AstraZeneca will invest $4.5bn into its new manufacturing facility in Virginia — a proposed increase of $500m — to support the enhanced manufacturing capability of a broader range of medicines, including cancer treatments.
This is part of the historic $50bn investment announced in July 2025.
The new facility will be located at Rivanna Futures in Albemarle County and is expected to create approximately 3600 direct and indirect jobs, powering economic growth and Virginia’s leadership at the forefront of life sciences innovation.
It will be at the forefront of technological innovation, leveraging AI, automation and data analytics to optimise production.
The new facility will produce drug substance for AstraZeneca’s weight management and metabolic portfolio, including oral GLP-1, baxdrostat, oral PCSK9 and combination small molecule products.
AstraZeneca is also announcing it has expanded the scope to include state-of-the-art manufacturing for its leading antibody drug conjugate (ADC) cancer portfolio.
Work will start immediately, with the facility expected to be operational in the next four to five years.
This investment will bring critical medicine manufacturing capabilities to the United States and offer assurance from a national security and health sovereignty perspective.
Dr Mehmet Oz, Centers for Medicare & Medicaid Services Administrator, said: “We cannot truly be a wealthy nation without being a healthy nation."
"Today's groundbreaking demonstrates the Trump Administration's commitment to onshoring drug manufacturing and strengthening supply chains to improve Americans' access to medication."
"I congratulate AstraZeneca for its investment and invite other foreign manufacturers to follow suit.”
Governor Glenn Youngkin, Commonwealth of Virginia, said: “AstraZeneca’s $4.5bn investment is the largest in the company’s history and a game-changer for American drug manufacturing."
"The investment is set to create 3600 jobs in Virginia, strengthening America’s ability to produce life-saving medicines."
"Thanks to programmes such as the Virginia Business Ready Sites programme and the Virginia Talent Accelerator programme, AstraZeneca is going to be able to hit the ground running."
"That means better jobs, better medicine and better opportunities for the people of Virginia.”
Pascal Soriot, Chief Executive Officer, AstraZeneca, said: “With our $4.5bn investment in Virginia, the largest in AstraZeneca’s history, we are not only building a state-of-the-art manufacturing facility, but also driving life sciences innovation and economic growth."
"This new facility will create thousands of jobs and strengthen America’s national security and health sovereignty."
"I also want to thank Governor Youngkin and his team for their energy and vision."
"We have found in Virginia an amazing team that moves at incredible speed to build a better future for this Commonwealth and the American people.”
The Virginia Economic Development Partnership worked with Albemarle County and the General Assembly’s Major Employment and Investment Project Approval Commission to secure the project for Virginia.